Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 5Rhabdomyosarcoma 4Osteosarcoma 3Carcinoma, Non-Small-Cell Lung 3Sarcoma, Synovial 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Pinealoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1

Interventions

cixutumumab 1Vincristine 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroectodermal Tumors × cixutumumab × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡